FORMULATION, QUALITY CONTROL AND SAFETY ISSUES OF NANOTECHNOLOGICAL MEDICINAL PRODUCTS

BIANCO, ISMAEL D.; CASADO, CRISTIAN; DABBENE, VIVIANA G.; RIZZI, CAROLINA; ARDANÁZ, EZEQUIEL; MARGARÍA, FEDERICO; MIZUTAMARI, R. KIYOMI

Buenos Aires

Jornada; XX JORNADAS ANUALES DE LA SOCIEDAD ARGENTINA DE BIOLOGÍA (SAB) - XVII JORNADAS DE LA SOCIEDAD URUGUAYA DE BIOCIENCIAS (SUB) - Segundas Jornadas Rioplatenses de Biología; 2018

Sociedad Argentina de Biología

Althoughwe have seen great advances, most human pathologies remain incurablebecause many patients either do not respond or relapse to treatment.Several lines of research are disclosing new therapeutic targetswhich lead to the development of new active drugs. However, there arestill unsolved problems related to stabilization of thepharmaceutical ingredient in aqueous and biological media,pharmacokinetic and pharmacodynamic profiles and cellular uptake toname just a few. In this context, nanotechnology with the emergingtools of nanoengineering offers many possibilities to guide thedesign of new products with improved safety and efficacy. Thepresence of several reacting groups and the sensitivity of theirproperties to small changes in composition make nanocarriers tunablenot only to modify their stability in a particular environment butalso to respond to changes in biological situations in the rightplace and time frame. Thistalk will summarize the main preparation methods and formulationstrategies of nano and microcarriers designed for drug deliveryapplications and will attempt to give a glimpse on how theirstructure, shape, physico-chemical properties and chemicalcomposition may affecttheir overall stability and interactions with biological systems. Achallenge with nanocarriers is that their biological activitiesdepend not only on their chemical composition but also on those ofthe structuresformed by them.From this, a very important issue that emerges is that nanocarriersfrequently display an intrinsic bioactivity (i.e.: immunomodulatory).Therefore, it should be stressed that nanocarriers cannot beconsidered as inert, biocompatible excipients. Asan approach to the rational design of new pharmaceutical productsnanoengineering is providing new tools for the precise control of theproperties of nanocarriers.p { margin-bottom: 0.25cm; direction: ltr; color: #000000; line-height: 120%; orphans: 2; widows: 2 }p.western { font-family: "Times New Roman", serif; font-size: 12pt; so-language: es-ES }p.cjk { font-family: "Times New Roman", serif; font-size: 12pt; so-language: zh-CN }p.ctl { font-family: "Times New Roman", serif; font-size: 12pt; so-language: ar-SA }